Source-grounded facts extracted from Aura Biosciences, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Jeremy Bender was appointed as Class II Director at Aura Biosciences, Inc..
“On July 3, 2026, the Board of Directors (the “Board”) of Aura Biosciences, Inc. (the “Company”) increased the size of the Board from six to seven directors and unanimously appointed Jeremy Bender, Ph.D., M.B.A., as a Class II director, effective July 7, 2026 (the “Effective Date”), to fill the newly created vacancy.”
Aura Biosciences, Inc. shareholders approved Ratification of Appointment of Independent Registered Accounting Firm at the 2026-06-11 meeting.
“Proposal 2 - Ratification of Appointment of Independent Registered Accounting Firm The Company’s stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026. Votes For Votes Against Abstentions 52,752,601 17,348 14,795 There were zero broker non-votes regarding this proposal.”
Aura Biosciences, Inc. shareholders approved Election of Class II Directors at the 2026-06-11 meeting.
“Proposal 1 - Election of Directors The Company’s stockholders elected the two (2) director nominees below to the Company’s Board of Directors as Class II directors to serve until the 2029 Annual Meeting of Stockholders of the Company and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal. Director Nominee Votes For Votes Withheld Broker Non-Votes David Johnson 34,542,193 6,628,297 11,614,254 Teresa Marie Bitetti 40,526,332 644,158 11,614,254”
Aura Biosciences, Inc. reported the first quarter ended March 31, 2026 results: net income $33.7 million.
“Net loss for the three months ended March 31, 2026, was $33.7 million, compared to $27.5 million for the three months ended March 31, 2025.”
Aura Biosciences, Inc. entered into Underwriting Agreement with Leerink Partners LLC, TD Securities (USA) LLC and Evercore Group L.L.C., as representatives of the several underwriters (effective 2026-05-04).
“On May 4, 2026, Aura Biosciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, TD Securities (USA) LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering”
Aura Biosciences, Inc. entered into Repurchase Agreement with Matrix Capital Management Master Fund, LP (effective 2026-04-30).
“On April 30, 2026, Aura Biosciences, Inc. (the “Company”) and Matrix Capital Management Master Fund, LP (“Matrix”) entered into a stock purchase agreement (the “Repurchase Agreement”)”
Elisabet de los Pinos departed as Director at Aura Biosciences, Inc..
“notified the Company of her departure from her role at the Company as Chief Executive Officer and President and as a director of the Company, effective as of the Effective Date”
Elisabet de los Pinos departed as Chief Executive Officer and President at Aura Biosciences, Inc..
“Dr. Elisabet de los Pinos, the Company’s founder, who has notified the Company of her departure from her role at the Company as Chief Executive Officer and President and as a director of the Company, effective as of the Effective Date”
Natalie Holles was appointed as Chief Executive Officer and President at Aura Biosciences, Inc..
“the Board of Directors (the “Board”) of Aura Biosciences, Inc. (the “Company”) appointed Natalie Holles as the Company’s Chief Executive Officer and President and as a Class I director with a term expiring at the Company’s 2028 annual meeting of stockholders, effective as of April 30, 2026”
Aura Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2025.
“Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided recent business highlights.”
Amy Elazzouzi changed role as Senior Vice President, Finance at Aura Biosciences, Inc..
“Beginning on the Effective Date, Amy Elazzouzi, the Company’s Senior Vice President, Finance, will cease serving as the Company’s principal financial officer and continue as the Company’s principal accounting officer and Mr. Gibney will serve as the Company’s principal financial officer.”
Anthony Gibney was appointed as Chief Financial and Business Officer at Aura Biosciences, Inc..
“Appointment of Chief Financial and Business Officer Effective as of May 13, 2025 (the “Effective Date”), the Board of Directors of the Company appointed Anthony Gibney as the Company’s Chief Financial and Business Officer.”
Teresa Marie Bitetti was appointed as Class II Director at Aura Biosciences, Inc..
“unanimously appointed Teresa Marie Bitetti, MBA, as a Class II director, effective March 31, 2025”
Amy Elazzouzi was appointed as interim principal financial officer and interim principal accounting officer at Aura Biosciences, Inc..
“On September 25, 2024, the Board of Directors of the Company (the “Board”) designated Amy Elazzouzi, the Company’s Vice President, Finance, as the Company’s interim principal financial officer and interim principal accounting officer, in each case, effective on the Transition Date, to serve in such roles during the pendency of the Company’s search for a new Chief Financial Officer.”
Julie Feder departed as Chief Financial Officer at Aura Biosciences, Inc..
“On September 23, 2024, Julie Feder notified Aura Biosciences, Inc. (the “Company”) of her departure from her role at the Company as an employee and Chief Financial Officer, effective as of October 25, 2024 (the “Transition Date”).”
Aura Biosciences, Inc. reported financial results for first quarter ended March 31, 2024.
“Aura Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024.”
Raj Parekh resigned as Director at Aura Biosciences, Inc..
“On April 12, 2024, Raj Parekh, Ph.D., notified Aura Biosciences, Inc. (the “Company”) of his intention to resign as a member of the Company’s board of directors (the “Board”), effective on June 20, 2024, the date of the Company’s 2024 annual meeting of stockholders.”
Aura Biosciences, Inc. reported financial results for fourth quarter and year ended December 31, 2023.
“On March 27, 2024, Aura Biosciences, Inc., issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023.”
Aura Biosciences, Inc. reported financial results for the third quarter ended September 30, 2023.
“On November 9, 2023, the Company issued a press release announcing its financial results for the quarter ended September 30, 2023.”
Aura Biosciences, Inc. entered into Underwriting Agreement with Leerink Partners LLC, Cowen and Company, LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein valued at approximately $92.6 million (effective 2023-11-06).
“On November 6, 2023, Aura Biosciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, Cowen and Company, LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell 11,000,000 shares of the Company’s common stock, par value $0.00001 per share (the “Common Stock”), to the Underwriters at a public offering price of $9.00 per share (the “Offering”).”
J. Jill Hopkins was appointed as Chief Medical Officer and President of Research & Development at Aura Biosciences, Inc..
“J. Jill Hopkins, M.D., will serve as the Company’s Chief Medical Officer and President of Research & Development, effective as of October 16, 2023”
Aura Biosciences, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023 was $18.3 million.
“On August 9, 2023, Aura Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.”
Aura Biosciences, Inc. shareholders approved Ratification of Appointment of Independent Registered Accounting Firm at the 2023-06-07 meeting.
“Proposal 2 - Ratification of Appointment of Independent Registered Accounting Firm The Company’s stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023. Votes For Votes Against Abstentions 25,725,525 3,721 1,826 There were zero broker non-votes regarding this proposal.”
Aura Biosciences, Inc. shareholders approved Election of Directors at the 2023-06-07 meeting.
“Proposal 1 - Election of Directors The Company’s stockholders elected the two (2) director nominees below to the Company’s Board of Directors as Class II directors to hold office until the 2026 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified. Director Nominee Votes For Votes Withheld Broker Non-Votes David Johnson 13,248,297 3,275,812 9,206,963 Karan Takhar 13,248,607 3,275,502 9,206,963”
Aura Biosciences, Inc. reported the quarter ended March 31, 2023 results: net income $17.5 million.
“On May 11, 2023, Aura Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023.”
Mark De Rosch resigned as Chief Operating Officer at Aura Biosciences, Inc..
“On April 3, 2023, Mark De Rosch informed Aura Biosciences, Inc. (the “Company”) of his intent to resign as Chief Operating Officer of the Company. Mr. De Rosch’s resignation will be effective on April 30, 2023.”
Aura Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.
“issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022.”
Aura Biosciences, Inc. entered into Underwriting Agreement with SVB Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C valued at 6,700,000 shares of common stock at $12.00 per share, with option for additional 1,005,000 shares (effective 2022-11-30).
“On November 30, 2022, Aura Biosciences, Inc. (the “Company”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with SVB Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C, as representatives of the several underwriters named therein (the “ Underwriters ”), pursuant to which the Company agreed to issue and sell 6,700,000 shares of the Company’s common stock, par value $0.00001 per share (the “ Common Stock ”), to the Underwriters at a public offering price of $12.00 per share (the “ Offering ”).”
Aura Biosciences, Inc. reported financial results for the quarter ended September 30, 2022.
“On November 10, 2022, Aura Biosciences Inc, (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.